Prognosis factors of cholangiocarcinoma: Contribution of recent molecular biology tools;Facteurs pronostiques des cholangiocarcinomes: Apport des données récentes de biologie moléculaire

Bulletin du Cancer

Volumn 96, Issue 4, 2009, Pages 405-415

  Malouf, G ^a   Dreyer, C ^a   Guedj, N ^a   Paradis, V ^a   Degos, F ^a   Belghiti, J ^a   Le Tourneau, C ^a   Faivre, S ^a   Raymond, E ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Biomarkers; Cholangiocarcinoma; Molecular biology; Molecular markers; Prognosis markers

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; MASPIN; MATRIX METALLOPROTEINASE; MUCIN; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAS PROTEIN; SMAD4 PROTEIN; SORAFENIB; SURVIVIN; TELOMERASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; UVOMORULIN; VASCULOTROPIN; VITAMIN D RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BILE DUCT CARCINOMA; CELL ADHESION; CELL CYCLE; CELL INVASION; CELL SURVIVAL; GENE; HUMAN; LYMPH NODE METASTASIS; MOLECULAR BIOLOGY; ONCOGENE; PROGNOSIS; REVIEW; TUMOR VOLUME;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL ADHESION; CELL CYCLE; CHOLANGIOCARCINOMA; HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 66349118989     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0780     Document Type: Review

References (81)

1. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999 ; 10 (Suppl 4) : 308-311 (Pubitemid 29333457)
2. Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005 ; 11 (12) : 1779-1784 (Pubitemid 40520767)
3. Raoul JL, Boucher E, Kerbrat P. Nonsurgical treatment of hepatocellular carcinoma. Bull Cancer 1999 ; 86 (6) : 537-543 (Pubitemid 29344006)
4. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996 ; 224 (4) : 463-473 (discussion 473-5).
5. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Pedersen R, Kremers W, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006 ; 82 (12) : 1703-1707 (Pubitemid 46035655)
6. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005 ; 29 (6) : 728-733 (Pubitemid 41187533)
7. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007 ; 96 (6) : 896-902. (Pubitemid 46452283)
8. Momoi H, Okabe H, Kamikawa T, Satoh S, Ikai I, Yamamoto M, et al. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res 2001 ; 7 (9) : 2648-2655 (Pubitemid 32911367)
9. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology 1995 ; 109 (5) : 1612-1617
10. Tang D, Nagano H, Yamamoto H, Wada H, Nakamura M, Kondo M, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006 ; 15 (3) : 525-532
11. Park BK, Paik YH, Park JY, Park KH, Bang S, Park SW, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol 2006 ; 29 (2) : 138-142 (Pubitemid 44270951)
12. Mobius C, Demuth C, Aigner T, Wiedmann M, Wittekind C, Mössner J, et al. Evaluation of VEGF-A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 2007. (Pubitemid 47408741)
13. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005 ; 280 (25) : 24053-24063 (Pubitemid 40884893)
14. Kim H, Yoo T, Park DI, Park JH, Cho YK, Sohn CI, et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Ann Oncol 2007 ; 18 (5) : 892-897 (Pubitemid 47054087)
15. Malaguarnera M, Di Fazio I, Laurino A, Romeo MA, Giugno I, Trovato BA. Role of interleukin-6 in hepatocellular carcinoma. Bull Cancer 1996 ; 83 (5) : 379-384
16. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T. Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 2006 ; 66 (21) : 10517-10524 (Pubitemid 44799774)
17. Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 2005 ; 41 (6) : 1339-1348 (Pubitemid 40770287)
18. Sasaki A, Kawano K, Aramaki M, Ohno T, Tahara K, Takeuchi Y, et al. Clinicopathologic study of mixed hepatocellular and cholangiocellular carcinoma: modes of spreading and choice of surgical treatment by reference to macroscopic type. J Surg Oncol 2001 ; 76 (1) : 37-46. (Pubitemid 32128361)
19. Kayahara M, Nagakawa T, Ohta T, Kitagawa H, Tajima H, Miwa K. Role of nodal involvement and the periductal soft-tissue margin in middle and distal bile duct cancer. Ann Surg 1999 ; 229 (1) : 76-83. (Pubitemid 30190383)
20. Hirohashi K, Uenishi T, Kubo S, Yamamoto T, Tanaka H, Shuto T, et al. Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes. Hepatogastroenterology 2002 ; 49 (44) : 326-329 (Pubitemid 34606544)
21. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001 ; 92 (9) : 2374-2383 (Pubitemid 33029082)
22. Kawarada Y, Yamagiwa K, Das BC. Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg 2002 ; 183 (6) : 679-685 (Pubitemid 34722537)
23. Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival. Eur J Surg Oncol 2007 ; 33 (2) : 202-207 (Pubitemid 46336554)
24. Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Clinical impact of the surgical margin status in hepatectomy for solitary mass-forming type intrahepatic cholangiocarcinoma without lymph node metastases. J Surg Oncol 2007 ; 96 (2) : 160-165 (Pubitemid 47264820)
25. Uenishi T, Hirohashi K, Shuto T, Tsukamoto T, Yamamoto T, Kubo S, et al. Surgically treated cases of mixed hepatocellular carcinoma and cholangiocarcinoma. Hepatogastroenterology 2002 ; 49 (46) : 1083-1086 (Pubitemid 34809792)
26. Morimoto Y, Tanaka Y, Ito T, Nakahara M, Nakaba H, Nishida T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003 ; 10 (6) : 432-440 (Pubitemid 38128793)
27. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007 ; 245 (5) : 755-762 (Pubitemid 46684105)
28. Jan YY, Yeh CN, Yeh TS, Hwang TL, Chen MF. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005 ; 29 (7) : 894-898 (Pubitemid 41800724)
29. Ramacciato G, Di Benedetto F, Cautero N, Masetti M, Mercantini P, Corigliano N, et al. Prognostic factors and long-term outcome after surgery for hilar cholangiocarcinoma. Univariate and multivariate analysis. Chir Ital 2004 ; 56 (6) : 749-759
30. Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H, et al. Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma. J Surg Oncol 2007 ; 95 (3) : 207-212 (Pubitemid 46310012)
31. Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery 2005 ; 137 (4) : 396-402. (Pubitemid 40432036)
32. Ramacciato G, Corigliano N, Mercantini P, Di Benedetto F, Masetti M, Ercolani G, et al. Prognostic factors after surgical resection for hilar cholangiocarcinoma. Ann Chir 2006 ; 131 (6-7) : 379-385 (Pubitemid 44036757)
33. Liu XF, Zhang H, Zhu SG, Zhou XT, Su HL, Xu Z, et al. Correlation of p53 gene mutation and expression of p53 protein in cholangiocarcinoma. World J Gastroenterol 2006 ; 12 (29) : 4706-4709 (Pubitemid 44269731)
34. Tannapfel A, Weinans L, Geissler F, Schütz A, Katalinic A, Köckerling F, et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci 2000 ; 45 (2) : 317-324 (Pubitemid 30133893)
35. Shrestha ML, Miyake H, Kikutsuji T, Tashiro S. Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J Med Invest 1998 ; 45 (1-4) : 95-102. (Pubitemid 128501271)
36. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002 ; 49 (45) : 604-608
37. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, et al. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 2006 ; 24 (7) : 1152-1160 (Pubitemid 46638813)
38. Horie S, Endo K, Kawasaki H, Terada T. Overexpression of mdm2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows Arch 2000 ; 437 (1) : 25-30.
39. Okaro AC, Deery AR, Hutchins RR, Davidson BR. The expression of antiapoptotic proteins Bcl-2, Bcl-x(l), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 2001 ; 54 (12) : 927-932 (Pubitemid 34032887)
40. Gross A, McDonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999 ; 13 (15) : 1899-1911 (Pubitemid 29407357)
41. Romani AA, Soliani P, Desenzani S, Borghetti AF, Crafa P. The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma. BMC Cancer 2006 ; 6 : 255. (Pubitemid 44741597)
42. Javle MM, Tan D, Yu J, LeVea CM, Li F, Kuvshinoff BW, et al. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 2004 ; 51 (60) : 1653-1657 (Pubitemid 39389751)
43. Zhu ZB, Chen Y, Makhija SK, Lu B, Wang M, Rivera AA, et al. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int J Oncol 2006 ; 29 (5) : 1319-1329
44. Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, et al. Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol 2006 ; 12 (26) : 4195-4198 (Pubitemid 44376901)
45. Ozaki S, Harada K, Sanzen T, Watanabe K, Tsui W, Nakanuma Y. In situ nucleic acid detection of human telomerase in intrahepatic cholangiocarcinoma and its preneoplastic lesion. Hepatology 1999 ; 30 (4) : 914-919
46. Limpaiboon T, Tapdara S, Jearanaikoon P, Sripa B, Bhudhisawasdi V. Prognostic significance of microsatellite alterations at 1p36 in cholangiocarcinoma. World J Gastroenterol 2006 ; 12 (27) : 4377-4382 (Pubitemid 44194532)
47. Thanasai J, Limpaiboon T, Jearanaikoon P, Bhudhisawasdi V, Khuntikeo N, Sripa B, et al. Amplification of D22S283 as a favorable prognostic indicator in liver fluke related cholangiocarcinoma. World J Gastroenterol 2006 ; 12 (27) : 4338-4344 (Pubitemid 44194526)
48. Nonomura A, Ohta G, Nakanuma Y, Izumi R, Mizukami Y, Matsubara F, et al. Simultaneous detection of epidermal growth factor receptor (EGFR), epidermal growth factor (EGF) and Ras p21 in cholangiocarcinoma by an immunocytochemical method. Liver 1988 ; 8 (3) : 157-166 (Pubitemid 18169100)
49. Fiorentino M, Altimari A, D'Errico A, Gabusi E, Chieco P, Masetti M, et al. Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res 2001 ; 7 (12) : 3994-3999 (Pubitemid 34044618)
50. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, et al. Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma. Oncology 2001 ; 60 (3) : 242-251 (Pubitemid 32424530)
51. Taguchi K, Aishima S, Asayama Y, Kajiyama K, Kinukawa N, Shimada M, et al. The role of p27kip1 protein expression on the biological behavior of intrahepatic cholangiocarcinoma. Hepatology 2001 ; 33 (5) : 1118-1123 (Pubitemid 32378210)
52. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996 ; 271 (5247) : 350-353
53. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, et al. Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 2001 ; 91 (7) : 1332-1341
54. Javle MM, Yu J, Khoury T, Chadha KS, Iyer RV, Foster J, et al. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol 2006 ; 21 (11) : 1744-1751 (Pubitemid 44410889)
55. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 2001 ; 197 (2) : 95-100. (Pubitemid 32194502)
56. Shimizu T, Yokomuro S, Mizuguchi Y, Kawahigashi Y, Arima Y, Taniai N, et al. Effect of transforming growth factor-beta-1 on human intrahepatic cholangiocarcinoma cell growth. World J Gastroenterol 2006 ; 12 (39) : 6316-6324 (Pubitemid 44712413)
57. Ohira S, Itatsu K, Sasaki M, Harada K, Sato Y, Zen Y, et al. Local balance of transforming growth factor-beta-1 secreted from cholangiocarcinoma cells and stromal-derived factor-1 secreted from stromal fibroblasts is a factor involved in invasion of cholangiocarcinoma. Pathol Int 2006 ; 56 (7) : 381-389 (Pubitemid 43886802)
58. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, et al. Transforming growth factor-beta-1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003 ; 63 (5) : 1083-1092 (Pubitemid 36278442)
59. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994 ; 9 (5) : 462-467 (Pubitemid 24312840)
60. Meng F, Yamagiwa Y, Ueno Y, Patel T. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 2006 ; 44 (6) : 1055-1065 (Pubitemid 44308229)
61. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003 ; 52 (5) : 706-712 (Pubitemid 36528874)
62. Rijken AM, van Gulik TM, Polak MM, Sturm PD, Gouma DJ, Offerhaus GJ. Diagnostic and prognostic value of incidence of K-ras codon 12 mutations in resected distal bile duct carcinoma. J Surg Oncol 1998 ; 68 (3) : 187-192 (Pubitemid 28359619)
63. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007 ; 6 (4) : 273-286
64. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000 ; 407 (6801) : 242-248
65. Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 2007 ; 5 (7) : 655-665
66. Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology 2004 ; 39 (1) : 220-229 (Pubitemid 38461485)
67. Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, et al. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 2006 ; 12 (14 Pt 1) : 4257-4264
68. Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, et al. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology 1999 ; 30 (6) : 1347-1355
69. Shirabe K, Shimada M, Kajiyama K, Hasegawa H, Gion T, Ikeda Y, et al. Expression of matrix metalloproteinase-9 in surgically resected intrahepatic cholangiocarcinoma. Surgery 1999 ; 126 (5) : 842-846 (Pubitemid 29523322)
70. Xiao M, Zhou NX, Huang ZQ, Lu YL, Chen LH, Wang DJ, et al. The ratio of MMP-2 to TIMP-2 in hilar cholangiocarcinoma: a semi-quantitative study. Hepatobiliary Pancreat Dis Int 2004 ; 3 (4) : 599-602. (Pubitemid 39561976)
71. Jo Chae K, Rha SY, Oh BK, Koo JS, Kim YJ, Choi J, et al. Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma. Am J Gastroenterol 2004 ; 99 (1) : 68-75. (Pubitemid 38679104)
72. Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer 2002 ; 94 (2) : 428-434 (Pubitemid 34081373)
73. Ashida K, Terada T, Kitamura Y, Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998 ; 27 (4) : 974-982 (Pubitemid 28160482)
74. Settakorn J, Kaewpila N, Burns GF, Leong AS. FAT, E-cadherin, beta-catenin, HER2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol 2005 ; 58 (12) : 1249-1254 (Pubitemid 41752767)
75. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, et al. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001 ; 14 (9) : 900-905 (Pubitemid 32889249)
76. Seubwai W, Wongkham C, Puapairoj A, Khuntikeo N, Wongkham S. Overexpression of vitamin D receptor indicates a good prognosis for cholangiocarcinoma: implications for therapeutics. Cancer 2007 ; 109 (12) : 2497-2505 (Pubitemid 46906469)
77. Nakagohri T, Asano T, Kinoshita H, Kenmochi T, Urashima T, Miura F, et al. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg 2003 ; 27 (3) : 289-293 (Pubitemid 36920139)
78. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Yamazaki O, Kinoshita H. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 2001 ; 88 (7) : 969-974 (Pubitemid 34015579)
79. Shimada K, Sano T, Sakamoto Y, Esaki M, Kosuge T, Ojima H. Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg 2007 ; 31 (10) : 2016-2022 (Pubitemid 47415732)
80. Valverde A, Bonhomme N, Farges O, Sauvanet A, Flejou JF, Belghiti J. Resection of intrahepatic cholangiocarcinoma: a Western experience. J Hepatobiliary Pancreat Surg 1999 ; 6 (2) : 122-127
81. Miwa S, Miyagawa S, Kobayashi A, Akahane Y, Nakata T, Mihara M, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006 ; 41 (9) : 893-900. (Pubitemid 44594231)